Truist Securities analyst Srikripa Devarakonda reiterated a Buy rating and $112.00 price target on Cytokinetics (NASDAQ: CYTK).The analyst comments "We ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE